QUINTILES ENTERS PACT ON DRUG

Quintiles Transnational will provide a Seattle-based biotechnology firm with $30 million in cash and services in return for at least $53 million in royalties. The Durham contract research organization announced the six-year pact between its PharmaBio Development arm and Cell Therapeutics. In it, Quintiles will pay CTI $25 million in cash and provide $5 million worth of clinical services.

The Herald-Sun (http://www.herald-sun.com/business/21-559668.html)